Beyond Pharma: How Bioprocessing Technologies Are Reshaping Food Production, Environmental Applications, and Sustainable Manufacturing

Bioprocessing technology industrial applications now extend well beyond the pharmaceutical sector. The bioreactor, the membrane filter, and the process analytical technology sensor were built for biopharma, but they are now driving the production of food ingredients, industrial enzymes, and biofuels at commercial scale, carrying the same engineering principles, hardware platforms, and monitoring strategies into industries where fermentation volumes are larger, regulatory frameworks are different, and economic pressures demand efficiency gains that rival those of drug manufacturing.

How industrial bioprocessing borrows from pharmaceutical manufacturing

Bioprocessing as a discipline emerged from pharmaceutical manufacturing, where the production of biologics under GMP conditions demanded precision fermentation, rigorous process control, and validated analytical methods. The instrumentation and engineering innovations developed to meet those demands are now sufficiently mature, and in many cases sufficiently affordable, to be applied profitably in industrial sectors where the product value per liter of fermentation broth is far lower but where production volumes are orders of magnitude larger.

Industrial enzyme manufacturing offers the clearest illustration of this transfer. The upstream bioprocessing workflows used to produce amylases, proteases, cellulases, and lipases at commercial scale depend on fed-batch or continuous fermentation processes that are mechanistically indistinguishable from those used to produce monoclonal antibodies, with the same requirements for dissolved oxygen control, pH management, nutrient feeding, and contamination prevention. The downstream recovery steps, including centrifugation, microfiltration, and ultrafiltration concentration, mirror the clarification and concentration operations performed in biopharmaceutical downstream processing. The technical overlap is direct enough that the scientific and operational literature covering upstream and downstream enzyme bioprocessing draws explicitly on methodologies developed in pharmaceutical biotechnology.

The distinction that matters most in practice is not the technology itself but the regulatory environment surrounding its use. In biopharma, every analytical method must be validated under ICH guidelines, every sensor must be qualified within a GMP framework, and every process deviation must be documented and investigated. In food-grade and industrial enzyme fermentation, the equivalent obligations are set by food safety regulations, current good manufacturing practice (cGMP) for food facilities, and customer quality agreements, all of which impose meaningful quality requirements but without the depth of documentation that pharmaceutical regulators mandate. Understanding where these frameworks converge and where they diverge is a prerequisite for organizations seeking to leverage biopharma-grade technology in industrial contexts.

PAT and fermentation monitoring in industrial bioprocessing

Process analytical technology (PAT) frameworks, first codified in the FDA's 2004 guidance document, established the rationale and regulatory architecture for real-time process monitoring in pharmaceutical manufacturing. The core principle, that measuring critical process attributes continuously and using that data to maintain a state of control is preferable to relying on endpoint testing, is as applicable to industrial fermentation as it is to biopharmaceutical bioreactor operation.

Raman spectroscopy has been the most actively investigated spectroscopic platform for this cross-sector transfer. Its insensitivity to water and compatibility with probe-based, non-invasive measurement configurations make it well suited to aqueous fermentation media across multiple production contexts. In biopharmaceutical fermentation, Raman probes are used to monitor glucose, lactate, glutamine, and product titer in real time; in industrial bioprocessing, the same measurement approach has been applied to monitor substrate consumption and metabolite accumulation in oleaginous yeast and marine microorganism fermentations, with Fourier transform Raman spectroscopy in recirculatory flow cell configurations demonstrating reliable online monitoring of biomass, lipid, and carbon substrate concentrations across different microbial systems. Research published in peer-reviewed literature confirms the applicability of Raman-based fermentation monitoring in industrial oleochemical and carotenoid production processes, with partial least squares regression models enabling quantitative prediction of critical process parameters in situ.

NIR spectroscopy occupies a complementary niche in industrial fermentation monitoring. Its strong signal for physical parameters, including total dissolved solids, biomass, and water content, makes it a natural fit for applications in brewing, dairy fermentation, and industrial enzyme production, where product consistency and substrate depletion monitoring represent the primary analytical objectives. The Food Safety Modernization Act and its implementing rules on preventive controls for food facilities create regulatory pull for more rigorous process documentation and control in food manufacturing, supporting the case for PAT adoption in food-grade fermentation environments. How Raman, NIR, and dissolved oxygen sensors developed in biopharma are being adapted for brewing, dairy fermentation, and industrial enzyme production, including the regulatory differences between food-grade and GMP bioprocessing environments, is examined in dedicated coverage on PAT and fermentation monitoring in food, beverage, and industrial bioprocessing.

Table 1: Comparison of bioprocessing technology applications across pharmaceutical and industrial sectors.

Industrial membrane filtration: from dairy and biofuels to biopharma

Tangential flow filtration (TFF) is among the most widely transferred bioprocessing technologies from pharmaceutical to industrial applications. In biopharma downstream processing, TFF serves two primary functions: harvest clarification through microfiltration to remove cells and debris, and ultrafiltration and diafiltration (UF/DF) to concentrate and buffer-exchange purified protein products. These same separation principles, directing larger species into the retentate while smaller molecules pass through membrane pores under transmembrane pressure, are applied in food ingredient concentration, dairy protein recovery, and industrial enzyme purification, with crossflow configurations preventing cake formation that would otherwise limit flux through the membrane.

In dairy processing, UF membranes are used to concentrate whey protein fractions and produce protein isolates with defined molecular weight cut-offs. Nanofiltration is applied in lactose reduction and demineralization steps. These are large-scale, continuous operations that bear direct technical resemblance to the concentration steps in biopharmaceutical downstream processing, despite operating under food safety rather than GMP regulatory requirements and processing product streams with very different economic profiles. The technical considerations that matter in both contexts, including membrane fouling management, transmembrane pressure control, and diafiltration buffer economics, are sufficiently similar that process engineers moving between sectors find most of the underlying knowledge directly transferable.

Industrial biofuel production presents another significant application domain for membrane separation. Ethanol and other fermentation-derived fuels require cell removal from broth, product concentration, and, in some processes, the separation of fermentation byproducts, all of which can be addressed with microfiltration, ultrafiltration, and nanofiltration configurations adapted from those used in pharmaceutical bioprocessing. An in-depth technical comparison of microfiltration, ultrafiltration, nanofiltration, and reverse osmosis across pharmaceutical, food ingredient, dairy, and biofuel production, including how crossflow filtration and TFF systems are being scaled and adapted for industrial biotechnology, is covered in dedicated coverage on membrane filtration in industrial bioprocessing.

Single-use bioprocessing systems in food and industrial fermentation

Single-use bioprocessing systems, comprising bioreactor bags, disposable fluid paths, pre-sterilized connectors, and integrated sensor assemblies, were adopted in biopharma primarily for their elimination of cleaning validation requirements, reduction of cross-contamination risk between products or batches, and acceleration of facility changeover. In an industry where a single failed cleaning validation can delay a product launch by months and where multi-product facilities require rigorous segregation between manufacturing campaigns, the operational arguments for disposable infrastructure are compelling even before capital cost comparisons are made.

Those same operational arguments are beginning to apply in industrial fermentation contexts, particularly where product changeover frequency is high or where the introduction of a new microbial organism into a facility creates contamination risk for existing production strains. Specialty enzyme producers, manufacturers of high-value fermented food ingredients, and early-stage industrial biotechnology companies developing novel bio-based chemicals are among the organizations where single-use bioreactor formats are seeing growing adoption, driven by the same flexibility and contamination-control rationale that drove pharma adoption rather than by formal GMP requirements.

The sustainability dimension of single-use systems is more contested in industrial contexts than in pharmaceutical ones. In biopharma, the plastic waste generated by disposable bioreactor bags, tubing assemblies, and fluid path components is a recognized and growing environmental challenge, one that the industry is beginning to address through vendor take-back programs, decontamination and recycling initiatives, and life cycle assessment comparisons of single-use vs stainless steel infrastructure. Industrial fermentation facilities, operating at much larger scales, face both greater waste volumes and greater economic pressure to address them. The operational and environmental strategies emerging in biopharma for reducing the footprint of single-use bioprocessing, including decontamination protocols, recyclable and bio-based materials development, and vendor sustainability programs, are covered in dedicated coverage on sustainability and waste reduction in single-use bioprocessing. The complementary water and buffer management strategies available to facilities seeking to reduce process water consumption and solvent waste are examined in the spoke article on sustainable filtration in bioprocessing.

Bioprocessing for environmental applications: membrane bioreactors and bioremediation

The most structurally distinct application of bioprocessing technology beyond the pharmaceutical sector is its deployment in environmental management, particularly in wastewater treatment and industrial effluent management. Membrane bioreactor (MBR) technology integrates biological degradation processes with membrane filtration for solid-liquid separation, replacing the secondary clarifiers used in conventional activated sludge systems with microfiltration or ultrafiltration membranes that retain suspended solids and biomass within the bioreactor. MBR systems can operate at higher mixed liquor suspended solids concentrations and extended sludge retention times compared with conventional treatment, and the retained microbial community can be optimized for the degradation of specific contaminants, including pharmaceutical residues, industrial chemicals, and emerging micropollutants.

The engineering principles underlying an MBR treating municipal wastewater are the same principles underlying a perfusion bioreactor retaining a mammalian cell culture, namely, continuous medium exchange with cell retention through membrane filtration, real-time monitoring of dissolved oxygen and pH, and control of biological activity through process parameters. The biological systems, regulatory frameworks, and economic constraints differ entirely; the core bioprocessing logic does not. Peer-reviewed research supports the effectiveness of membrane bioreactors for contaminant removal from both municipal and industrial wastewater sources, including the removal of micropollutants that conventional treatment technologies cannot reliably eliminate.

Improving Efficiency in Routine PFAS Analysis Using EPA Methods 533 and 1633A

In this webinar, explore a practical approach to PFAS analysis using EPA Methods 533 and 1633A, with application data illustrating low-level quantitation, accuracy and precision in quality control samples, chromatographic separation of challenging in
View Webinar

Advertisement

Bioremediation applications extend MBR concepts further. In industrial effluent treatment, engineered microbial consortia operating in bioreactor configurations can degrade organic contaminants, including phenols, hydrocarbons, dyes, and halogenated compounds from chemical, textile, and food processing wastewaters. The same principles of aerobic microbial metabolism that govern mammalian cell culture in a pharmaceutical bioreactor, including dissolved oxygen management, nutrient supply, pH control, and biomass management, govern the performance of a bioremediation reactor treating contaminated industrial effluent.

Advances in microbial engineering for wastewater treatment confirm that process optimization strategies borrowed from fermentation bioprocessing, including bioaugmentation, consortium design, and real-time monitoring, are producing measurable improvements in treatment efficiency for difficult-to-remediate effluents. The technical and regulatory dimensions of applying bioreactors, MBRs, fermentation monitoring, and PAT tools to wastewater treatment and industrial effluent management are examined in dedicated coverage on bioprocessing for environmental applications.

Regulatory differences between pharma and industrial bioprocessing

The most common failure mode in technology transfer from pharmaceutical to industrial bioprocessing is underestimating how much regulatory context shapes equipment design, operational practice, and validation requirements. A single-use bioreactor bag qualified for pharmaceutical use under USP <665>, the standard governing extractables and leachables testing for polymeric components in drug manufacturing, carries a documentation package that justifies a price premium acceptable to a biopharma manufacturer but economically inaccessible to a commodity enzyme producer. The same bag chemistry, without the qualification documentation, might be entirely fit for purpose in an industrial fermentation context but would require the industrial manufacturer to assess its suitability under applicable food contact materials regulations rather than pharmaceutical standards.

Similarly, a Raman spectroscopy method validated under ICH Q2(R2) guidelines for quantitative measurement of a biopharmaceutical process parameter cannot simply be transferred to an industrial fermentation application and declared equivalent. The calibration model must be built on samples representative of the new process matrix, the measurement conditions must be assessed for relevance to the industrial fermentation environment, and the performance criteria must be defined against the analytical objectives of the industrial application rather than the pharmaceutical method validation requirements. This does not make the transfer difficult; it makes it structured, and organizations with the domain knowledge to navigate it are positioned to capture significant process efficiency advantages.

The practical transfer of PAT-grade process analytics into industrial and environmental bioprocessing is also constrained by the economics of calibration maintenance and sensor qualification. Research demonstrating Raman-enabled metabolite prediction in Saccharomyces cerevisiae fermentations illustrates how combining cell-free media sampling with advanced chemometric modeling can address fluorescence interference challenges that would otherwise limit spectroscopic monitoring in industrial microbial fermentation. Advances in machine learning-based calibration approaches are reducing the front-loaded investment required to deploy spectroscopic monitoring in new fermentation contexts, making the business case increasingly viable on grounds of process efficiency and yield improvement, even without a GMP compliance mandate. The convergence between pharmaceutical-grade and industrial-grade bioprocessing is accelerating as regulatory expectations for food and industrial manufacturers increase, as sensor costs decline, and as the workforce trained in pharmaceutical bioprocessing brings those operational standards into adjacent sectors.

Bioprocessing technology industrial applications: the convergence ahead

Bioprocessing technology industrial applications represent one of the most significant areas of growth for the vendors, instrumentation platforms, and process knowledge that originated in pharmaceutical manufacturing. The common thread running through food ingredient fermentation, industrial enzyme production, biofuel manufacturing, and environmental bioprocessing is the application of microbial metabolism at scale, with controlled process conditions, real-time monitoring, and efficient product recovery, to generate value from biological systems. These are exactly the problems that the pharmaceutical bioprocessing sector spent four decades solving, and the solutions it developed are now finding commercial traction well beyond the industries that funded that development.

The trajectory is toward greater standardization of bioprocessing tools across sectors, with modular and scalable hardware platforms, flexible single-use infrastructure, and increasingly accessible PAT systems enabling a wider range of industrial operators to implement process control strategies previously achievable only by organizations with the capital and regulatory expertise of large pharmaceutical manufacturers. The environmental and sustainability pressures bearing on all manufacturing sectors are further accelerating this convergence, as circular economy principles and ESG commitments require the same data-driven process efficiency from industrial biotechnology that GMP requirements have long demanded from pharmaceutical manufacturing. The broader instrumentation, regulatory, and digital infrastructure context for this shift is examined in the cluster hub on process analytics and QC testing, which covers the real-time measurement frameworks spanning both pharmaceutical and industrial bioprocessing.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.